Article Sidebar

PDF
Date Published: 08/01/2022
Abstract Views: 137
Views PDF: 145
DOI: https://doi.org/10.51298/vmj.v508i2.1628
Issue
Vol. 508 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Vân Anh, L. ., Thị Thái Hòa, N. ., & Văn Hiếu, N. . (2022). EVALUATION OF THE TREATMENT OUTCOMES OF PEMETREXED IN SECOND-LINE TREATMENT OF LUNG ADENOCARCINOMA STAGE IV. Vietnam Medical Journal, 508(2). https://doi.org/10.51298/vmj.v508i2.1628

EVALUATION OF THE TREATMENT OUTCOMES OF PEMETREXED IN SECOND-LINE TREATMENT OF LUNG ADENOCARCINOMA STAGE IV

Lê Thị Vân Anh1,, Nguyễn Thị Thái Hòa2, Nguyễn Văn Hiếu1
1 Hanoi Medical University
2 K Hospital

Main Article Content

Abstract

Objective: To evaluateprogression-free survival and side effects of Pemetrexed in second-line treatment of patients with lung adenocarcinoma stage IV at K hospital from January 2017 to August 2021. Methods: Combined retrospective and prospectivelongitudinal study in 33 patients with lung adenocarcinoma stage IV treated with Pemetrexed after progression on platinum-containing first-line chemotherapy. Results: Median progression-free survival was 3.4 months. There were no significant differences in median PFS between subgroups in terms of age and sex. The median PFS of patients with better performance status (ECOG) was superior compared to those with poorer ECOG (p=0.029) . Toxicity: The regimen was well tolerated. The most common toxicities were anemia, elevated transaminases, fatigue, and nausea which all at grade 1-2 toxicity. No patients experienced grade 3-4 toxicity. Conclusion: Pemetrexed is an reasonable, effective, and safe optionfor the second-line treatment of metastatic lung adenocarcinoma priorly treated with platinum-containing chemotherapy.

Article Details

Keywords

Lung adenocarcinoma, second-line treatment, progression-free survival

References

1. Trần Văn Thuấn (2019), Hướng dẫn chẩn đoán và điều trị bệnh ung thư thường gặp, Nhà xuất bản Y học, Hà Nội.
2. International Agency for Research on Cancer (2018). Globocan 2018- Vietnam. WHO.
3. National Comprehensive Cancer Network (NCCN) (2020), Non-small cell lung cancer, NCCN Clinical Practice Guidelines in Oncology, Version 3.2020.
4. Dela Cruz C.S., Tanoue L.T., and Matthay R.A. (2011). Lung Cancer: Epidemiology, Etiology, and Prevention. Clinics in Chest Medicine, 32(4), 605–644.
5. Tomasini P., Barlesi F., Mascaux C., et al. (2016). Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes:. Therapeutic Advances in Medical Oncology.
6. Hanna N., Shepherd F.A., Fossella F.V., et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22(9), 1589–1597.
7. Pujol J.-L., Paul S., Chouaki N., et al. (2007). Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol, 2(5), 397–401.
8. Bùi Công Toàn- Hoàng Đình Chân (2008), Bệnh ung thư phổi, Nhà xuất bản Y học.
9. Trần Nguyên Bảo (2014). Đánh giá hiệu quả điều trị Docetaxel trong điều trị bước 2 UTPKTBN tại Bệnh viện Ung Bướu Hà Nội. Luận văn thạc sĩ Y học, Đại Học Y Hà Nội.